thymine has been researched along with Colonic Neoplasms in 49 studies
Colonic Neoplasms: Tumors or cancer of the COLON.
| Excerpt | Relevance | Reference |
|---|---|---|
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 9.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 8.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 8.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 8.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 8.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of 5FU and MTX are critically dependent on cellular composition of folates." | 7.72 | Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Sohn, KJ; Yates, Z, 2004) |
| " fluoropyrimidine and irinotecan plus bevacizumab (control) as second-line treatment for metastatic colorectal cancer (mCRC)." | 5.69 | Trifluridine/tipiracil+bevacizumab (BEV) vs. fluoropyrimidine-irinotecan+BEV as second-line therapy for metastatic colorectal cancer: a randomised noninferiority trial. ( Hara, H; Ishihara, S; Kagawa, Y; Kajiwara, T; Kawakami, H; Kotaka, M; Kuboki, Y; Makiyama, A; Masuishi, T; Morita, S; Nakajima, TE; Nakamura, M; Ojima, H; Oki, E; Ozawa, D; Shirao, K; Sugimoto, N; Sunakawa, Y; Takashima, A; Takenaka, N; Taniguchi, H; Terazawa, T; Watanabe, J; Yoshino, T, 2023) |
| "For patients with refractory metastatic colorectal cancer (mCRC) treatment with Trifluridine/Tipiracil, also known as TAS-102, improves overall survival." | 4.12 | Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer. ( Ananda, S; Banks, S; Dunn, C; Gard, G; Gately, L; Gibbs, P; Jalali, A; Jennens, R; Khattak, A; Kosmider, S; Lee, B; Lee, M; Lim, L; Loft, M; McKendrick, J; Shapiro, JD; Tie, J; Wong, HL; Wong, R; Yeung, JM, 2022) |
| "The aim of this analysis is to assess the pharmacological costs of trifluridine/tipiracil as first-line treatment in metastatic colorectal cancer (mCRC) patients who were not candidates for combination with cytotoxic chemotherapies." | 4.12 | Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness. ( Giuliani, J, 2022) |
| "The RECOURSE trial supported trifluridine/tipiracil as a treatment option in metastatic colorectal cancer (mCRC)." | 4.12 | The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis. ( Basto, R; Bonito, N; Gomes, I; Jacinto, P; Magalhães, J; Paulo, J; Pereira, TC; Sousa, G; Sousa, MJ, 2022) |
| "Regorafenib (R) and trifluridine/tipiracil (FTD/TPI) are of proven efficacy in metastatic colorectal cancer (mCRC) patient's refractory to standard therapies." | 4.12 | Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study". ( Artru, P; Bouché, O; Coriat, R; Coutzac, C; De La Fouchardière, C; Doat, S; Gallois, C; Henriques, J; Masson, T; Moulin, V; Saint, A; Taieb, J; Tougeron, D; Trouilloud, I; Vernerey, D, 2022) |
| "The RECOURSE trial demonstrated a modest benefit in overall survival (OS) for trifluridine/tipiracil (FTD/TPI) versus placebo in pretreated metastatic colorectal cancer (mCRC) patients." | 4.12 | Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS). ( Dijksterhuis, WPM; Elferink, MAG; Hamers, PAH; Koopman, M; May, AM; Punt, CJA; Stellato, RK; Vink, GR, 2022) |
| " We hypothesized that this polymorphism may modulate the cytotoxic effect of 5-fluorouracil (5FU) and methotrexate (MTX), two commonly used chemotherapeutic agents for colon and breast cancers, because the modes of action of 5FU and MTX are critically dependent on cellular composition of folates." | 3.72 | Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate. ( Croxford, R; Kim, YI; Lucock, M; Sohn, KJ; Yates, Z, 2004) |
| "Trifluridine/tipiracil is an oral chemotherapeutic agent recently approved for third-line treatment of chemorefractory metastatic colorectal cancer." | 2.58 | Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers. ( Cervantes, A; Moreno Vera, S; Peeters, M; Taieb, J, 2018) |
| " TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD." | 2.53 | TAS-102 an Emerging Oral Fluoropyrimidine. ( Chen, J; Han, M; Saif, MW, 2016) |
| "More than 50% of colon cancer-associated mutations in the p53 tumor suppressor gene are C-->T transitions." | 2.41 | Thymine DNA glycosylase. ( Bentele, M; Hardeland, U; Jiricny, J; Lettieri, T; Schär, P; Steinacher, R, 2001) |
| "Trifluridine/tipiracil is a treatment used in refractory metastatic digestive cancers." | 1.56 | IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report. ( Brochériou, I; Desbuissons, G; Fournier, P; Ngango, L, 2020) |
| "Trifluridine (TFT) is an antitumor component of a novel nucleoside antitumor agent, TAS-102, which consists of TFT and tipiracil hydrochloride (thymidine phosphorylase inhibitor)." | 1.42 | Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse. ( Chiba, M; Komoto, I; Kuwata, K; Nakagawa, F; Oka, H; Takeuchi, M; Yamashita, F; Yoshisue, K, 2015) |
| "The Hollow Fibre Assay (HFA) is usually applied as an early in vivo model for anti-cancer drug screening, but is potentially an excellent model for short-term in vivo pharmacodynamic studies." | 1.34 | The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells. ( Peters, GJ; Prins, HJ; Temmink, OH; van Gelderop, E, 2007) |
| " Our hypothesis was that a relatively short and high dosage of TAS-102 results in an additional mechanism of FTD incorporation into DNA other than thymidylate synthase (TS) inhibition." | 1.32 | A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. ( Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (12.24) | 18.7374 |
| 1990's | 6 (12.24) | 18.2507 |
| 2000's | 10 (20.41) | 29.6817 |
| 2010's | 12 (24.49) | 24.3611 |
| 2020's | 15 (30.61) | 2.80 |
| Authors | Studies |
|---|---|
| Jalali, A | 1 |
| Gard, G | 1 |
| Banks, S | 1 |
| Dunn, C | 1 |
| Wong, HL | 1 |
| Wong, R | 1 |
| Lee, M | 1 |
| Gately, L | 1 |
| Loft, M | 1 |
| Shapiro, JD | 1 |
| Kosmider, S | 1 |
| Tie, J | 1 |
| Ananda, S | 1 |
| Yeung, JM | 1 |
| Jennens, R | 1 |
| Lee, B | 1 |
| McKendrick, J | 1 |
| Lim, L | 1 |
| Khattak, A | 1 |
| Gibbs, P | 1 |
| Schouten, JF | 1 |
| Willems, J | 1 |
| Sanders, SJWJ | 1 |
| Creemers, GJ | 1 |
| Deenen, MJ | 1 |
| Giuliani, J | 1 |
| Sousa, MJ | 1 |
| Gomes, I | 1 |
| Pereira, TC | 1 |
| Magalhães, J | 1 |
| Basto, R | 1 |
| Paulo, J | 1 |
| Jacinto, P | 1 |
| Bonito, N | 1 |
| Sousa, G | 1 |
| Coutzac, C | 1 |
| Trouilloud, I | 1 |
| Artru, P | 1 |
| Henriques, J | 1 |
| Masson, T | 1 |
| Doat, S | 1 |
| Bouché, O | 1 |
| Coriat, R | 1 |
| Saint, A | 1 |
| Moulin, V | 1 |
| Vernerey, D | 1 |
| Gallois, C | 1 |
| De La Fouchardière, C | 1 |
| Tougeron, D | 1 |
| Taieb, J | 2 |
| Hamers, PAH | 1 |
| Vink, GR | 1 |
| Elferink, MAG | 1 |
| Stellato, RK | 1 |
| Dijksterhuis, WPM | 1 |
| Punt, CJA | 1 |
| Koopman, M | 1 |
| May, AM | 1 |
| Yoshino, T | 6 |
| Van Cutsem, E | 4 |
| Li, J | 2 |
| Shen, L | 1 |
| Kim, TW | 2 |
| Sriuranpong, V | 1 |
| Xuereb, L | 1 |
| Aubel, P | 1 |
| Fougeray, R | 1 |
| Cattan, V | 1 |
| Amellal, N | 1 |
| Ohtsu, A | 4 |
| Mayer, RJ | 1 |
| Martínez-Lago, N | 1 |
| Chucla, TC | 1 |
| De Castro, BA | 1 |
| Ponte, RV | 1 |
| Rendo, CR | 1 |
| Rodriguez, MIG | 1 |
| Diaz, SS | 1 |
| Suarez, BG | 1 |
| de la Cámara Gomez, J | 1 |
| Fernández, FB | 1 |
| Salvador, MM | 1 |
| Lopez, MR | 1 |
| Hochster, H | 3 |
| Shitara, K | 3 |
| Mayer, R | 3 |
| Falcone, A | 4 |
| Doi, T | 3 |
| Ilson, DH | 3 |
| Arkenau, HT | 3 |
| George, B | 3 |
| Benhadji, KA | 3 |
| Makris, L | 3 |
| Tabernero, J | 3 |
| Kuboki, Y | 1 |
| Terazawa, T | 1 |
| Masuishi, T | 2 |
| Nakamura, M | 1 |
| Watanabe, J | 1 |
| Ojima, H | 1 |
| Makiyama, A | 2 |
| Kotaka, M | 1 |
| Hara, H | 1 |
| Kagawa, Y | 1 |
| Sugimoto, N | 1 |
| Kawakami, H | 1 |
| Takashima, A | 2 |
| Kajiwara, T | 2 |
| Oki, E | 2 |
| Sunakawa, Y | 1 |
| Ishihara, S | 1 |
| Taniguchi, H | 2 |
| Nakajima, TE | 1 |
| Morita, S | 1 |
| Shirao, K | 1 |
| Takenaka, N | 1 |
| Ozawa, D | 1 |
| Shiroyama, M | 1 |
| Fukuoka, S | 1 |
| Kumekawa, Y | 1 |
| Yamazaki, K | 1 |
| Shimada, Y | 1 |
| Esaki, T | 1 |
| Moriwaki, T | 1 |
| Chen, J | 2 |
| Wang, J | 1 |
| Lin, H | 1 |
| Peng, Y | 1 |
| Desbuissons, G | 1 |
| Ngango, L | 1 |
| Brochériou, I | 1 |
| Fournier, P | 1 |
| Suetsugu, T | 1 |
| Mori, R | 1 |
| Futamura, M | 1 |
| Fukada, M | 1 |
| Tanaka, H | 1 |
| Yasufuku, I | 1 |
| Sato, Y | 1 |
| Iwata, Y | 1 |
| Imai, T | 1 |
| Imai, H | 2 |
| Tanaka, Y | 2 |
| Okumura, N | 1 |
| Matsuhashi, N | 2 |
| Takahashi, T | 2 |
| Yoshida, K | 2 |
| Nakamura, Y | 1 |
| Kotani, D | 1 |
| Yukami, H | 1 |
| Mishima, S | 1 |
| Sawada, K | 1 |
| Shirasu, H | 1 |
| Ebi, H | 1 |
| Yamanaka, T | 1 |
| Aleshin, A | 1 |
| Billings, PR | 1 |
| Rabinowitz, M | 1 |
| Takemasa, I | 1 |
| Kato, T | 1 |
| Mori, M | 1 |
| Baba, Y | 1 |
| Tamura, T | 1 |
| Satoh, Y | 1 |
| Gotou, M | 1 |
| Sawada, H | 1 |
| Ebara, S | 1 |
| Shibuya, K | 1 |
| Soeda, J | 1 |
| Nakamura, K | 1 |
| Takano, J | 1 |
| Tanahashi, T | 1 |
| Matsui, S | 1 |
| Yamaguchi, K | 1 |
| Peeters, M | 1 |
| Cervantes, A | 1 |
| Moreno Vera, S | 1 |
| Orlandi, P | 1 |
| Gentile, D | 1 |
| Banchi, M | 1 |
| Cucchiara, F | 1 |
| Di Desidero, T | 1 |
| Cremolini, C | 1 |
| Moretto, R | 1 |
| Bocci, G | 1 |
| Carriles, C | 1 |
| Jimenez-Fonseca, P | 1 |
| Sánchez-Cánovas, M | 1 |
| Pimentel, P | 1 |
| Carmona-Bayonas, A | 1 |
| García, T | 1 |
| Carbajales-Álvarez, M | 1 |
| Lozano-Blázquez, A | 1 |
| Silva, SLR | 1 |
| Baliza, IRS | 1 |
| Dias, RB | 1 |
| Sales, CBS | 1 |
| Rocha, CAG | 1 |
| Soares, MBP | 1 |
| Correa, RS | 1 |
| Batista, AA | 1 |
| Bezerra, DP | 1 |
| Tanaka, N | 1 |
| Sakamoto, K | 1 |
| Okabe, H | 1 |
| Fujioka, A | 1 |
| Yamamura, K | 1 |
| Nakagawa, F | 2 |
| Nagase, H | 1 |
| Yokogawa, T | 1 |
| Oguchi, K | 1 |
| Ishida, K | 1 |
| Osada, A | 1 |
| Kazuno, H | 1 |
| Yamada, Y | 1 |
| Matsuo, K | 1 |
| Lee, HJ | 2 |
| Oh, SJ | 1 |
| Lee, EJ | 1 |
| Chung, JH | 1 |
| Kim, Y | 1 |
| Ryu, JS | 1 |
| Kim, SY | 1 |
| Lee, SJ | 1 |
| Moon, DH | 1 |
| Yamashita, F | 1 |
| Komoto, I | 1 |
| Oka, H | 1 |
| Kuwata, K | 1 |
| Takeuchi, M | 1 |
| Yoshisue, K | 1 |
| Chiba, M | 1 |
| Han, M | 1 |
| Saif, MW | 1 |
| Fangkangwanwong, J | 1 |
| Sae-Liang, N | 1 |
| Sriworarat, C | 1 |
| Sereemaspun, A | 1 |
| Chirachanchai, S | 1 |
| Toffoli, G | 1 |
| Gafà, R | 1 |
| Russo, A | 1 |
| Lanza, G | 1 |
| Dolcetti, R | 1 |
| Sartor, F | 1 |
| Libra, M | 1 |
| Viel, A | 1 |
| Boiocchi, M | 1 |
| Sohn, KJ | 1 |
| Croxford, R | 1 |
| Yates, Z | 1 |
| Lucock, M | 1 |
| Kim, YI | 1 |
| Emura, T | 1 |
| Suzuki, N | 1 |
| Yamaguchi, M | 1 |
| Ohshimo, H | 1 |
| Fukushima, M | 1 |
| Temmink, OH | 1 |
| Prins, HJ | 1 |
| van Gelderop, E | 1 |
| Peters, GJ | 2 |
| Hong, YS | 1 |
| You, CH | 1 |
| Roh, MS | 1 |
| Kwak, JY | 1 |
| Lee, MJ | 1 |
| Kim, JY | 1 |
| Kang, MY | 1 |
| Lee, BB | 1 |
| Ji, YI | 1 |
| Jung, EH | 1 |
| Chun, HK | 1 |
| Song, SY | 1 |
| Park, SE | 1 |
| Park, J | 1 |
| Kim, DH | 1 |
| Au, JL | 1 |
| Rustum, YM | 1 |
| Ledesma, EJ | 1 |
| Mittelman, A | 1 |
| Creaven, PJ | 1 |
| Schmutte, C | 1 |
| Yang, AS | 1 |
| Beart, RW | 1 |
| Jones, PA | 1 |
| Schwartz, EL | 1 |
| Baptiste, N | 1 |
| O'Connor, CJ | 1 |
| Wadler, S | 1 |
| Otter, BA | 1 |
| Houghton, JA | 3 |
| Harwood, FG | 3 |
| Tillman, DM | 2 |
| Nemunaitis, J | 1 |
| Cox, J | 1 |
| Meyer, W | 1 |
| Courtney, A | 1 |
| Mues, G | 1 |
| van Groeningen, CJ | 1 |
| Pinedo, HM | 1 |
| Kasibhatla, S | 1 |
| Petak, I | 2 |
| Vernes, R | 1 |
| Green, DR | 1 |
| Mihalik, R | 1 |
| Pauly, GT | 1 |
| Moschel, RC | 1 |
| Hardeland, U | 1 |
| Bentele, M | 1 |
| Lettieri, T | 1 |
| Steinacher, R | 1 |
| Jiricny, J | 1 |
| Schär, P | 1 |
| Day, RS | 2 |
| Yarosh, DB | 1 |
| Fornace, AJ | 1 |
| Wolberg, WH | 2 |
| Nielsen, HR | 1 |
| Nyholm, K | 1 |
| Sjolin, KE | 1 |
| Van Way, CW | 1 |
| Reynolds, VH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I/II Trial of TS-1 and Oxaliplatin in Patients With Advanced Colorectal Cancer[NCT00531245] | Phase 1/Phase 2 | 77 participants (Anticipated) | Interventional | 2006-08-31 | Completed | ||
| Efficacy and Safety of Trifluridine/Tipiracil in Combination With Irinotecan as a Second Line Therapy in Patients With Cholangiocarcinoma[NCT04059562] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-10-28 | Active, not recruiting | ||
| Phase II Trial of TAS-102 in Patients With Advanced, Refractory Pancreatic Adenocarcinoma[NCT04923529] | Phase 2 | 28 participants (Anticipated) | Interventional | 2021-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for thymine and Colonic Neoplasms
| Article | Year |
|---|---|
Effect of KRAS codon 12 or 13 mutations on survival with trifluridine/tipiracil in pretreated metastatic colorectal cancer: a meta-analysis.
Topics: Codon; Colonic Neoplasms; Colorectal Neoplasms; Frontotemporal Dementia; Humans; Mutation; Proto-Onc | 2022 |
Comparison of Regorafenib, Fruquintinib, and TAS-102 in Previously Treated Patients with Metastatic Colorectal Cancer: A Systematic Review and Network Meta-Analysis of Five Clinical Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzofurans; Colonic Neoplasms; Colorectal Neoplasms | 2019 |
Trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Clinical Trials as Topic; | 2018 |
TAS-102 an Emerging Oral Fluoropyrimidine.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols | 2016 |
Thymine DNA glycosylase.
Topics: Amino Acid Sequence; Animals; Bacterial Proteins; Base Pair Mismatch; Base Sequence; Cell Transforma | 2001 |
3 trials available for thymine and Colonic Neoplasms
41 other studies available for thymine and Colonic Neoplasms
| Article | Year |
|---|---|
Initial experience of TAS-102 chemotherapy in Australian patients with Chemo-refractory metastatic colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Australia; Colonic Neoplasms; Colorectal Neoplasms; | 2022 |
Standard-Dose Trifluridine/Tipiracil as Safe Treatment Alternative in Metastatic Colorectal Cancer Patients With DPD Deficiency.
Topics: Colonic Neoplasms; Dihydropyrimidine Dehydrogenase Deficiency; Humans; Pyrrolidines; Rectal Neoplasm | 2021 |
Trifluridine/Tipiracil in Combination with Bevacizumab in First-Line for Metastatic Colorectal Cancer: A Way Forward. A Point of View Based on Cost-Effectiveness.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
The effect of prognostic factors at baseline on the efficacy of trifluridine/tipiracil in patients with metastatic colorectal cancer: A Portuguese exploratory analysis.
Topics: Aged; Colonic Neoplasms; Colorectal Neoplasms; Female; Humans; Liver Neoplasms; Male; Portugal; Prog | 2022 |
Sequential Treatment With Trifluridine/Tipiracil and Regorafenib in Refractory Metastatic Colorectal Cancer Patients: An AGEO Prospective "Real-World Study".
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2022 |
Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Colonic Neoplasms; Colorectal Neoplasms | 2022 |
Renal impairment as a risk factor for trifluridine/tipiracil-induced adverse events in metastatic colorectal cancer patients from the REGOTAS study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Colorectal Neoplasms; Drug Combin | 2023 |
IgA Nephropathy Associated with Trifluridine/Tipiracil: A Case Report.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Glomerulonephritis, IGA; Hu | 2020 |
Mechanism of acquired 5FU resistance and strategy for overcoming 5FU resistance focusing on 5FU metabolism in colon cancer cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; C | 2021 |
Panitumumab interaction with TAS-102 leads to combinational anticancer effects via blocking of EGFR-mediated tumor response to trifluridine.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Ne | 2017 |
[A Case of Metastatic Colorectal Cancer with Brain Metastasis Treated with Combined TFTD and Bevacizumab Therapy].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Colonic Neoplasm | 2018 |
Reply to P. Di Nardo et al and R. Sun et al.
Topics: Colonic Neoplasms; Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Thymine; Trifluridi | 2018 |
Pharmacological effects of the simultaneous and sequential combinations of trifluridine/tipiracil (TAS-102) and 5-fluorouracil in fluoropyrimidine-sensitive colon cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Colonic Neoplasms; Dr | 2020 |
Trifluridine/Tipiracil (TAS-102) for refractory metastatic colorectal cancer in clinical practice: a feasible alternative for patients with good performance status.
Topics: Adult; Aged; Aged, 80 and over; Colonic Neoplasms; Drug Administration Schedule; Drug Combinations; | 2019 |
Ru(II)-thymine complex causes DNA damage and apoptotic cell death in human colon carcinoma HCT116 cells mediated by JNK/p38/ERK1/2 via a p53-independent signaling.
Topics: Apoptosis; Cell Line, Tumor; Colon; Colonic Neoplasms; DNA Damage; HCT116 Cells; Humans; MAP Kinase | 2019 |
Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colonic | 2014 |
Positron emission tomography imaging of human colon cancer xenografts in mice with [18F]fluorothymidine after TAS-102 treatment.
Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Colonic Neoplasms; Dideoxyn | 2015 |
Exposure-dependent incorporation of trifluridine into DNA of tumors and white blood cells in tumor-bearing mouse.
Topics: Animals; Antineoplastic Agents; Bone Marrow Cells; Cell Line, Tumor; Cell Proliferation; Colonic Neo | 2015 |
Water-Based Chitosan for Thymine Conjugation: A Simple, Efficient, Effective, and Green Pathway to Introduce Cell Compatible Nucleic Acid Recognition.
Topics: Cell Line; Cell Survival; Chitosan; Circular Dichroism; Colonic Neoplasms; DNA; Electrophoretic Mobi | 2016 |
Methylenetetrahydrofolate reductase 677 C-->T polymorphism and risk of proximal colon cancer in north Italy.
Topics: Alleles; Colonic Neoplasms; Cytosine; DNA Methylation; Gene Silencing; Genotype; Humans; Italy; Meth | 2003 |
Effect of the methylenetetrahydrofolate reductase C677T polymorphism on chemosensitivity of colon and breast cancer cells to 5-fluorouracil and methotrexate.
Topics: Alanine; Animals; Antimetabolites, Antineoplastic; Blotting, Western; Breast Neoplasms; Cell Line, T | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neop | 2004 |
The Hollow Fibre Assay as a model for in vivo pharmacodynamics of fluoropyrimidines in colon cancer cells.
Topics: Administration, Oral; Animals; Apoptosis; Capecitabine; Cell Cycle; Cell Line, Tumor; Colonic Neopla | 2007 |
DNMT3b 39179GT polymorphism and the risk of adenocarcinoma of the colon in Koreans.
Topics: Adenocarcinoma; Asian People; Base Sequence; Case-Control Studies; Colonic Neoplasms; DNA (Cytosine- | 2007 |
Association of interindividual differences in p14ARF promoter methylation with single nucleotide polymorphism in primary colorectal cancer.
Topics: Adenine; Colonic Neoplasms; CpG Islands; Cytosine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytos | 2008 |
Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Topics: Colonic Neoplasms; Drug Therapy, Combination; Floxuridine; Fluorouracil; Humans; Infusions, Parenter | 1982 |
Base excision repair of U:G mismatches at a mutational hotspot in the p53 gene is more efficient than base excision repair of T:G mismatches in extracts of human colon tumors.
Topics: Base Sequence; Colonic Neoplasms; Deoxyribonuclease (Pyrimidine Dimer); DNA Glycosylases; DNA Repair | 1995 |
Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary effects on thymidine phosphorylase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Deoxyribonucleosides; Drug Synerg | 1994 |
Thymineless death in colon carcinoma cells is mediated via fas signaling.
Topics: Apoptosis; Colonic Neoplasms; Enzyme Inhibitors; Fas Ligand Protein; fas Receptor; Humans; Membrane | 1997 |
Irinotecan hydrochloride (CPT-11) resistance identified by K-ras mutation in patients with progressive colon cancer after treatment with 5-fluorouracil (5-FU).
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents, Phy | 1997 |
Dihydropyrimidine dehydrogenase in livers from mouse and rat, and in human liver, colon tumors, and mucosa in relation to anabolism of 5-fluorouracil.
Topics: Animals; Biological Availability; Biotransformation; Colonic Neoplasms; Dihydrouracil Dehydrogenase | 1998 |
Regulation of FasL by NF-kappaB and AP-1 in Fas-dependent thymineless death of human colon carcinoma cells.
Topics: Apoptosis; Cell Survival; Clone Cells; Colonic Neoplasms; DNA-Binding Proteins; Fas Ligand Protein; | 2000 |
Fas-dependent and -independent mechanisms of cell death following DNA damage in human colon carcinoma cells.
Topics: Amino Acid Chloromethyl Ketones; Antigens, Surface; Apoptosis; Caspases; Cell Death; Clone Cells; Co | 2000 |
Mutagenesis by O(6)-methyl-, O(6)-ethyl-, and O(6)-benzylguanine and O(4)-methylthymine in human cells: effects of O(6)-alkylguanine-DNA alkyltransferase and mismatch repair.
Topics: Base Pair Mismatch; Colonic Neoplasms; Escherichia coli; Genetic Vectors; Guanine; Humans; Kidney; L | 2001 |
Incision at O6-methylguanine:thymine mispairs in DNA by extracts of human cells.
Topics: Base Composition; Base Sequence; Binding, Competitive; Colonic Neoplasms; Deoxyribonuclease I; DNA; | 1992 |
Human O6-alkylguanine-DNA alkyltransferase fails to repair O4-methylthymine and methyl phosphotriesters in DNA as efficiently as does the alkyltransferase from Escherichia coli.
Topics: Alkylation; Cell Line; Cells, Cultured; Colonic Neoplasms; DNA Repair; Escherichia coli; HeLa Cells; | 1985 |
Biochemical approaches to prediction of response in solid tumors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbon Isotopes; Carcinoma, Hepatocellular; Carcinoma, Squamo | 1971 |
Relationship between urinary beta-aminoisobutyric acid and transfer RNA turnover in cancer patients.
Topics: Aged; Aminoisobutyric Acids; Carcinoma, Transitional Cell; Colonic Neoplasms; DNA, Neoplasm; Female; | 1974 |
Response of DNA thymine synthesis in human tumor and normal tissue to 5-fluorouracil.
Topics: Breast Neoplasms; Carbon Isotopes; Chromatography, Paper; Colon; Colonic Neoplasms; Depression, Chem | 1972 |
A new method for treatment of carcinoma of the breast and colon with 5-fluorouracil.
Topics: Adult; Aged; Breast Neoplasms; Chemical Phenomena; Chemistry; Colonic Neoplasms; Female; Fluorouraci | 1970 |